Genmab — Marts 2019
-
"And what is also encouraging is that Janssen recently, they also have a BCMA CD3 bispecific program using our DuoBody technology….& said in the business update that they intend to actually combine their BCMA CD3 bispecific together with daratumumab and not compete with daratumumab, and that is probably the right thing to do also for the BCMA ADC from Glaxo and potentially for Amgen's BCMA BiTE molecule."
-
Tak for reminderen E L.
-
Lidt svært helt at gennemskue, men 54% af patienterne var "Stage I" og alle ECOG 0 eller 1 (70% 1). Tidligere behandlinger fra 1 til over 10. 14 en eller anden slags Dara behandling tidligere. Safety lidt svær at vurdere da procenterne er procenter af alle, selv om kun 22 af 35 gennemførte (så tallene kan være for små - måske). De fremhæver selv at dette er det hidtil bedste, der er set efter Dara
-
Genmab Announces European Regulatory Submission for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
Company Announcement Type II variation application submitted to the EMA for daratumumab in combination with lenalidomide and dexamethasone as treatment...
GlobeNewswire News Room (www.globenewswire.com)
-
Tror først det bliver efter påske
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind